Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2023-05-08
2028-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
REsting and Stimulus-based Paradigms to Detect Organized NetworkS and Predict Emergence of Consciousness
NCT03504709
Physiology of Human Brain Connectivity
NCT06246942
Study of Low-intensity Focused Ultrasound Effects on Cognitive fMRI Signals
NCT05303428
The Impact of Reward-induced Dopamine Release on Functional Connectivity: a Combined PET/fMRI Study
NCT02801643
Neuronal Integrity in Bipolar Depression
NCT04855409
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
MRI or fMRI scan: the purpose of the MR scan is to help us identify the different regions of the brain on the PET scans. Participants may be asked to do some cognitive and behavioral tasks during parts of the MR scan.
PET scan: an arterial catheter and one or two IV catheters will be placed (one for radiotracer injection and one to take blood samples). The radiotracer, \[18F\]SDM-8 will be used. A radiotracer is a minimal amount of a drug that is labeled with a very small amount of a radioactive substance that binds to receptors in the brain and can be detected by a special camera in the PET scanner.
Electroencephalography (EEG): EEG is a procedure that allows measurement of physiological brain responses. Sensors placed on and around the head record small electrical currents produced by the brain.
Follow-up phone calls and appointments: participants will have follow-up phone calls every 3 months for 9 months following scan visits, and an in-person follow-up appointment 1 year after scans to assess mood and cognition, as well as document any changes. Follow-up assessments may continue for up to 5 years after the year one follow-up appointment.
Some subjects may be asked to return after the 1 year follow-up period to repeat study procedures to examine changes over time.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Transdiagnostic
Participants will be a transdiagnostic sample of older individuals (age 55+ years) with stress disorders without psychosis including individuals with MDD, bipolar disorder, post-traumatic stress disorder (PTSD), dysthymia, and non-psychiatric individuals.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age 55+
* English speaking
Exclusion Criteria
* for women: pregnancy or breastfeeding
* serious medical or neurological illness that in the opinion of the PI would interfere with the scientific goals of the study or participant safety
* pervasive developmental disorders (PDD) or primary psychotic disorders
* meet DSM-5 criteria for current severe substance use disorder (except marijuana or nicotine)
* head injury that led to significant long term decline in cognitive abilities as seen by decline in grades or work performance
* current psychosis, active significant suicidal (score of 6 on MADRS suicide item) or homicidal ideation
* lifetime history of neurologic abnormality including seizure disorder, cerebrovascular, or neoplastic lesion, neurodegenerative disorder, or significant head trauma resulting in post-traumatic amnesia \>24 hours
* full scale IQ lower than 70
* contraindications to PET (e.g. poor venous access for placement of venous lines)
* history of prior radiation exposure for research purposes within the past year such that participation in this study would place them over FDA limits for annual radiation exposure. This guideline is an effective dose of 5 rem received per year
* history of a bleeding disorder or currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto) \*for subjects obtaining arterial line.
* blood donation within 8 weeks of the start of the study
* REM sleep disorder
* brain injury (TBI, seizure/epilepsy, stroke, TIA) in lifetime (self-report and medical chart review)
* electroconvulsive or ketamine therapy, or similar therapies that have rapid effects on brain neurochemistry within the past 6 months
* high risk for stroke (above first quartile on Framingham Stroke Risk Profile)
* current cancer
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Irina Esterlis
Professor of Psychiatry
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Irina Esterlis, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yale Translational Brain Imaging Program
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2000033973
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.